## PATENT COOPERATION TREAT

The second secon

From the INTERNATIONAL SEARCHING AUTHORITY To: JANE MASSEY LICATA LICATA & TYRRELL P.C. 66 E. MAIN STREET NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT MARLTON, NJ 08053 OR THE DECLARATION **Docket System** Status Report (PCT Rule 44.1) **Docket Book** Date of Mailing 11/7/04 07 SEP 2004 (day/month/year) Applicant's or agent's file reference See paragraphs 1 and 4 below FOR FURTHER ACTION DEX-0450 International filing date International application No. (day/month/year) PCT/US03/38808 04 December 2003 (04.12.2003) Applicant DIADEXUS, INC. The applicant is hereby notified that the international search report has been established and is transmitted herewith. Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46): The time limit for filing such amendments is normally two months from the date of transmittal of the When? international search report. Where? Directly to the International Bureau of WIPO, 34, chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35 For more detailed instructions, see the notes on the accompanying sheet. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that: the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made. Reminders Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the completion of the technical preparations for international publication. Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months. See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide,

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Volume II, National Chapters and the WIPO Internet site.

Facsimile No. (703)872-9306 Form PCT/ISA/220 (April 2002) Authorized officer

James Martinell

Telephone No. (571) 272-1600

(See notes on accompanying sheet)

7. Roberts for

# PATENT COOPERATION TREATY

# **PCT**

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference DEX-0450  |  | FOR FURTHER ACTION   |             | e Notification of Transmittal of International Search Report<br>Form PCT/ISA/220) as well as, where applicable, item 5 |  |  |  |  |
|---|--|--|-------------|--|--|--|--|--|
| International application No.<br>PCT/US03/38808   |  | International filing date (day/month/year) 04 December 2003 (04.12.2003) |             | (Earliest) Priority Date (day/month/year)<br>04 December 2002 (04.12.2002)   |  |  |  |  |
| Applicant DIADEXUS, INC.  |  |  |             |  |  |  |  |  |
| This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.  This international search report consists of a total of sheets. |  |  |             |  |  |  |  |  |
| It is also accompanied by a copy of each prior art document cited in this report.   |  |  |             |  |  |  |  |  |
| Basis of the Report     a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.   |  |  |             |  |  |  |  |  |
| the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).   |  |  |             |  |  |  |  |  |
| b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:  |  |  |             |  |  |  |  |  |
|   | contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form. |  |             |  |  |  |  |  |
|   |  |  |             |  |  |  |  |  |
|   | furnished subsequently to this Authority in computer readable form.  |  |             |  |  |  |  |  |
|   | the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.                               |  |             |  |  |  |  |  |
|   | the statement that the infor-<br>been furnished.   | mation recorded in computer readal                                       | ole form is | identical to the written sequence listing has  |  |  |  |  |
| 2.  | Certain claims were found  | d unsearchable (See Box I).  |             |  |  |  |  |  |
| 3. With a   | Unity of invention is lacking (See Box II).  Vith regard to the title,   |  |             |  |  |  |  |  |
| 4. With re  | the text is approved as sub  | mitted by the applicant  |             |  |  |  |  |  |
|   | ••   | d by this Authority to read as follow                                    | ws:         |  |  |  |  |  |
| 5. With re  | 5. With regard to the abstract,  |  |             |  |  |  |  |  |
|   | the text is approved as subs   | mitted by the applicant.   |             |  |  |  |  |  |
|   |  |  |             | ty as it appears in Box III. The applicant report, submit comments to this   |  |  |  |  |
| 6. The figure of the drawings to be published with the abstract is Figure No.   |  |  |             |  |  |  |  |  |
|   | as suggested by the applica  | nt.  |             | None of the figures  |  |  |  |  |
|   | because the applicant failed   | l to suggest a figure.   |             |  |  |  |  |  |
|   | because this figure better c   | haracterizes the invention.  |             |  |  |  |  |  |

Form PCT/ISA/210 (first sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/US03/38808

| Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|
| This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:  |  |  |  |  |  |  |
| 1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  |  |  |  |  |  |  |
| Claim Nos.:<br>because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:   |  |  |  |  |  |  |
| 3. Claim Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule  6.4(a).   |  |  |  |  |  |  |
| Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)  |  |  |  |  |  |  |
| This International Searching Authority found multiple inventions in this international application, as follows:  Please See Continuation Sheet  .  |  |  |  |  |  |  |
| <ol> <li>As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.</li> <li>As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.</li> <li>As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:</li> </ol> |  |  |  |  |  |  |
| <ul> <li>No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10 and 15-17 as they pertain to nucleic acids encoding SEQ ID NO: 95.</li> <li>Remark on Protest</li> <li>The additional search fees were accompanied by the applicant's protest.</li> <li>No protest accompanied the payment of additional search fees.</li> </ul>  |  |  |  |  |  |  |
| !  |  |  |  |  |  |  |

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38808

| A. CLASSIFICATION OF SUBJECT MATTER  |   |                                |   |                                  |  |  |  |  |
|--|---|--------------------------------|---|----------------------------------|--|--|--|--|
| IPC(7) : C12Q 1/68; C12P 21/02; C12N 15/00, 15/12, 15/11; A61K 31/7088, 31/711 US CL : 536/23.1, 23.5; 435/6, 320.1, 325, 252.3, 69.1; 514/44                |   |                                |   |                                  |  |  |  |  |
| According to International Patent Classification (IPC) or to both national classification and IPC  |   |                                |   |                                  |  |  |  |  |
| B. FIELDS SEARCHED   |   |                                |   |                                  |  |  |  |  |
| Minimum documentation searched (classification system followed by classification symbols)  |   |                                |   |                                  |  |  |  |  |
| U.S.: 536/23.1, 23.5; 435/6, 320.1, 325, 252.3, 69.1; 514/44   |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                                |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                                 |   |                                |   |                                  |  |  |  |  |
| Compugen, SEQ ID NOs: 1 and 95   |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
| C. DOC   | UMENTS CONSIDERED TO BE RELEVANT  |                                |   |                                  |  |  |  |  |
| Category *   | Citation of document, with indication, where a                          | <u> </u>                       |   | Relevant to claim No.            |  |  |  |  |
| X  | WO 95/15084 A1 (LXR BIOTECHNOLOGY INC                                   | 1-6 and 8-10                   |   |                                  |  |  |  |  |
|  | especially Claim 4, Figures 3A-3C, and pages 3 ar                       |                                |   |                                  |  |  |  |  |
|  | nucleotides 212-830 to Figure 3A-3C, nucleotides                        |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  | ,   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                | j   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
|  |   |                                |   |                                  |  |  |  |  |
| Further  | documents are listed in the continuation of Box C.                      |                                | See patent family annex.  |                                  |  |  |  |  |
| * S  | pecial categories of cited documents:                                   | *T*                            | later document published after the inte   | mational filing date or priority |  |  |  |  |
| "A" document   | defining the general state of the art which is not considered to be     |                                | date and not in conflict with the applic<br>principle or theory underlying the inve |                                  |  |  |  |  |
|  | lar relevance   |                                |   |                                  |  |  |  |  |
| "E" earlier ap   | plication or patent published on or after the international filing date | "X"                            | document of particular relevance; the<br>considered novel or cannot be consider     |                                  |  |  |  |  |
| •  | . , ,   |                                | when the document is taken alone  |                                  |  |  |  |  |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as |   | *Y*                            | document of particular relevance; the claimed invention cannot be                   |                                  |  |  |  |  |
| specified)   |   |                                | considered to involve an inventive step<br>combined with one or more other such     |                                  |  |  |  |  |
| "O" document   | referring to an oral disclosure, use, exhibition or other means         |                                | being obvious to a person skilled in the  |                                  |  |  |  |  |
| "P" document   | nublished prior to the international filing date but later than the     | *&"                            | document member of the same patent  | family                           |  |  |  |  |
| "P" document published prior to the international filing date but later than the<br>priority date claimed  |   |                                | Localization of the state parents   |                                  |  |  |  |  |
| Date of the actual completion of the international search  |   |                                | Date of mailing of the interpasional search report                                  |                                  |  |  |  |  |
| •  |   |                                | 07 SEP 2004   | •                                |  |  |  |  |
| 20 August 2004 (20.08.2004)  |   |                                | ad affina   |                                  |  |  |  |  |
| Name and mailing address of the ISA/US   |   |                                | Authorized officer  |                                  |  |  |  |  |
| Mail Stop PCT, Attn: ISA/US Commissioner for Patents   |   | James Martinell 7. Roberts for |   |                                  |  |  |  |  |
| P.O. Box 1450  |   |                                | ie No. (571) 272-1600   |                                  |  |  |  |  |
| Alexandria, Virginia 22313-1450  Facsimile No. (703)872-9306   |   |                                |   |                                  |  |  |  |  |
| 1 desition (10.) (10.) (1.2-7.300  |   |                                |   |                                  |  |  |  |  |

Form PCT/ISA/210 (second sheet) (July 1998)

# PCT/USU3/38808 INTERNATIONAL SEARCH REPORT BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid. Group I, claim(s) 1-10, and 15-17 drawn to nucleic acids, nucleic acid molecular hybridization assays, vectors, host cells, methods for producing polypeptides, kits, vaccines, and methods of treatment using nucleic acids. Group II, claim(s) 11, 12, and 16-18, drawn to polypeptides, kits, vaccines, and methods of treatment using polypeptides. Group III, claim(s) 13-15, drawn to antibodies and protein binding assays. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The nucleic acids, vectors, host cells, nucleic acid containing kits, and nucleic acid vaccines of Group I are materially different from the polypeptides, kits containing polypeptides, and polypeptide vaccines of Group II, and the antibodies of Group III. The methods of Group I may be practiced without the products or compositions of Group II or the antibodies of Group III. The methods of Groups I-III may be practiced independently of one another. The polypeptides and vaccines of Group II are materially different from the antibodies of Group III and are not needed to practice the methods of Group III. Each of the Groups mentions or requires the use of 248 separate and unrelated nucleic acids and/or polypeptides; thus the total number of inventions is 3 x 248 = 744. Each of the Groups mentions or requires the use of a large number of separate and unrelated nucleic acids and/or polypeptides. No matter which additional Group(s) applicant elects, applicant is further required to select for search one SEQ ID NO within the Group(s) for search. Any additional SEQ ID NO to be searched requires one additional search fee per SEQ ID NO. In the absence of payment of additional search fee(s) the first mentioned SEQ ID NO in Group I (i.e. SEQ ID NO: 95) will be searched. Should applicant pay fee(s) for additional Groups to be searched, the first mentioned SEQ ID NO within the selected Group will be searched unless applicant directs otherwise.

#### NOTESTO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

#### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

#### NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

# The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
  "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- 3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]: "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

#### "Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

#### It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

#### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

## Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide,